Evidence-Based Integrative Medicine

, Volume 2, Issue 1, pp 13–18

Green Tea Polyphenols

Promising Substances for Prostate Cancer Chemoprevention
Review Article


Basic research has identified some nutrients as agents that inhibit mutagenesis and hyperproliferation, as well as some that induce apoptosis or differentiation, which are critical characteristics for chemoprevention regardless of the nutrient’s specific molecular targets. Some of the most promising nutrients identified as chemopreventive agents in prostate cancer are green tea polyphenols. The components of green tea are epigallocatechin-3-gallate [(−)-EGCG], epigallocatechin [(−)-EGC], epicatechin-3-gallate [(−)-ECG], epicatechin [(−)-EC] and their epimers (−)-GCG, (−)-CG, (−)-GC and (−)-C. Of these components, (−)-EGCG has been the most extensively investigated because of its relative abundance and strong cancer-preventive properties. Recently, several epidemiological, animal and laboratory studies have demonstrated the cancer-preventive properties of green tea polyphenols, specifically in prostate cancer. This article reviews the evidence to date in the role of green tea polyphenols in prostate cancer, and the future directions of this field of research.


  1. 1.
    Cancer facts and figures. Atlanta (GA): American Cancer Society, 2005Google Scholar
  2. 2.
    Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276(16): 13322–30PubMedCrossRefGoogle Scholar
  3. 3.
    Kazi A, Smith DM, Daniel KG, et al. Potential molecular targets of tea polyphenols in human cancer: significance in cancer prevention (invited review). In Vivo 2002; 16: 1–7Google Scholar
  4. 4.
    Kazi A, Wang Z, Kumar N, Falsetti SC, Chan TH, Dou QP. Structure-activity relationships of synthetic analogs of (−)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res 2004 Mar–Apr; 24(2B): 943–54PubMedGoogle Scholar
  5. 5.
    Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004 May; 62(5): 204–11PubMedCrossRefGoogle Scholar
  6. 6.
    Ahmad N, Mukhtar H. Cutaneous photochemoprotection by green tea: a brief review. Skin Pharmacol Appl Skin Physiol 2001; 14(2): 69–76PubMedCrossRefGoogle Scholar
  7. 7.
    Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004; 28: 629–33PubMedCrossRefGoogle Scholar
  8. 8.
    Kronz JD, Allan CH, Shaikh AA, et al. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001 Aug; 25(8): 1079–85PubMedCrossRefGoogle Scholar
  9. 9.
    Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005 Jun 15; 11(12): 4627–33PubMedCrossRefGoogle Scholar
  10. 10.
    Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004 Mar; 17(3): 360–79PubMedCrossRefGoogle Scholar
  11. 11.
    Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004 Nov 15; 101(10 Suppl.): 2371–490PubMedCrossRefGoogle Scholar
  12. 12.
    Gokden N, Roehl KA, Catalona WJ, et al. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. Urology 2005 Mar; 65(3): 538–42PubMedCrossRefGoogle Scholar
  13. 13.
    Naya Y, Ayala AG, Tamboli P, et al. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004 Mar; 63(3): 503–8PubMedCrossRefGoogle Scholar
  14. 14.
    San Francisco IF, Olumi AF, Kao J, et al. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. BJU Int 2003 Mar; 91(4): 350–4PubMedCrossRefGoogle Scholar
  15. 15.
    Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59(2): 141–7PubMedCrossRefGoogle Scholar
  16. 16.
    Office of Dietary Supplements, National Institutes of Health. Botanical dietary supplements: background information [online]. Available from URL: http://ods.od.nih.gov/factsheets/BotanicalBackground.asp#h2 [Accessed 2005 Jun 3]
  17. 17.
    Sabar R, Kaye AD, Frost EA. Perioperative considerations for the patient taking herbal medicines. Heart Dis 2001; 3: 87–96PubMedCrossRefGoogle Scholar
  18. 18.
    Kumar NB, Hopkins K, Allen K, et al. Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice. Cancer Control 2002; 9: 236–43PubMedGoogle Scholar
  19. 19.
    Newman V, Rock CL, Faerber S, et al. Dietary supplement use by women at risk for breast cancer recurrence: the Women’s Healthy Eating and Living Study Group. J Am Diet Assoc 1998; 98: 285–92PubMedCrossRefGoogle Scholar
  20. 20.
    Morris KT, Johnson N, Homer L, et al. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 2000; 179: 407–11PubMedCrossRefGoogle Scholar
  21. 21.
    Sawyer MG, Gannoni AF, Toogood IR, et al. The use of alternative therapies by children with cancer. Med J Aust 1994; 160: 320–2PubMedGoogle Scholar
  22. 22.
    Lippert MC, McClain R, Boyd JC, et al. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999; 86: 2642–8PubMedCrossRefGoogle Scholar
  23. 23.
    Burstein HJ, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340: 1733–9PubMedCrossRefGoogle Scholar
  24. 24.
    Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 1999; 161: 1521–4PubMedCrossRefGoogle Scholar
  25. 25.
    Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedracontaining dietary supplements. Am J Health Syst Pharm 2000; 57: 963–9PubMedGoogle Scholar
  26. 26.
    Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999; 125: 589–97PubMedCrossRefGoogle Scholar
  27. 27.
    Yang CS. Tea and health. Nutrition 1999; 15: 946–9PubMedCrossRefGoogle Scholar
  28. 28.
    Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev 1999; 57: 78–83PubMedCrossRefGoogle Scholar
  29. 29.
    Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998; 31(3): 151–9PubMedCrossRefGoogle Scholar
  30. 30.
    Nelson WG. Agents in development for prostate cancer prevention. Expert Opin Investig Drugs 2004 Dec; 13(12): 1541–54PubMedCrossRefGoogle Scholar
  31. 31.
    Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004 Jan 1; 108(1): 130–5PubMedCrossRefGoogle Scholar
  32. 32.
    Gupta S, Hastak K, Ahmad N, et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001 Aug 28; 98(18): 10350–5PubMedCrossRefGoogle Scholar
  33. 33.
    Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003 Sep 15; 66(6): 965–76PubMedCrossRefGoogle Scholar
  34. 34.
    Nyska A, Suttie A, Bakshi S, et al. Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural anti-oxidant from spinach, NAO: a comparative study of three anti-oxidants. Toxicol Pathol 2003 Jan–Feb; 31(1): 31–8PubMedGoogle Scholar
  35. 35.
    Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003 Jul; 133(7 Suppl.): 2417S–24SPubMedGoogle Scholar
  36. 36.
    Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human CaP specimens [published erratum appears in Cancer Res 2000 Mar 1; 60 (5): 1472]. Cancer Res 2000; 60: 28–34PubMedGoogle Scholar
  37. 37.
    Leskov KS, Klokov DY, Li J, et al. Synthesis and functional analysis of the nuclear clusterin, a cell death protein. J Biol Chem 2003; 278: 11590–600PubMedCrossRefGoogle Scholar
  38. 38.
    Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2,ApoJ) expression is downregulated in low-and high-grade human prostate cancer. Int J Cancer 2004; 108: 23–30PubMedCrossRefGoogle Scholar
  39. 39.
    Bettuzzi S, Scorcioni F, Astancolle S, et al. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalised human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002; 21: 4328–34PubMedCrossRefGoogle Scholar
  40. 40.
    Grassilli E, Bettuzzi S, Monti D, et al. Studies on the relationship between cell proliferation and cell death: opposite patterns of SGP-2 and ornithine decarboxylase mRNA accumulation in PHA-stimulated human lymphocytes. Biochem Biophys Res Commun 1991; 180: 59–63PubMedCrossRefGoogle Scholar
  41. 41.
    July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in CaP cells following androgen withdrawal therapy. Prostate 2002; 50: 179–88PubMedCrossRefGoogle Scholar
  42. 42.
    Pucci S, Bonanno E, Pichiorri F, et al. Modulation of different Clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298–304PubMedCrossRefGoogle Scholar
  43. 43.
    Sartippour MR, Heber D, Ma J, et al. Green tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 2001; 40(2): 149–56PubMedCrossRefGoogle Scholar
  44. 44.
    Kavanagh KT, Hafer LJ, Kim DW, et al. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 2001; 82(3): 387–98PubMedCrossRefGoogle Scholar
  45. 45.
    Liao S, Umekita Y, Guo J, et al. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995; 96: 239–43PubMedCrossRefGoogle Scholar
  46. 46.
    Gupta S, Ahmad N, Mohan RR et al. CaP chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999; 59: 2115–20PubMedGoogle Scholar
  47. 47.
    Wang ZY, Huang MT, Ho CT, et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1992; 52: 6657–65PubMedGoogle Scholar
  48. 48.
    Taniguchi S, Fujiki H, Kobayashi H, et al. Effect of (−)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992; 65: 51–4PubMedCrossRefGoogle Scholar
  49. 49.
    Pianetti S, Guo S, Kavanagh KT, et al. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 2002 Feb 1; 62(3): 652–5PubMedGoogle Scholar
  50. 50.
    Kao YH, Hiipalla RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000; 141(3): 980–7PubMedCrossRefGoogle Scholar
  51. 51.
    Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001; 480-481: 243–68PubMedCrossRefGoogle Scholar
  52. 52.
    Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001 May 3; 20(20): 2499–513PubMedCrossRefGoogle Scholar
  53. 53.
    Segev DL, Hoshiya Y, Hoshiya M, et al. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 2001; 276(29): 26799–806PubMedCrossRefGoogle Scholar
  54. 54.
    Liang YC, Lin-Shiau SY, Chen CF, et al. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997; 67: 55–65PubMedCrossRefGoogle Scholar
  55. 55.
    Chung JY, Huang C, Meng X, et al. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 1999; 59: 4610–7PubMedGoogle Scholar
  56. 56.
    Liang YC, Lin-Shiau SY, Chen CF, et al. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. J Cell Biochem 1999; 75: 1–12PubMedCrossRefGoogle Scholar
  57. 57.
    Ullmann U, Haller J, Decourt JD, et al. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int J Vitam Nutr Res 2004 Jul; 74(4): 269–78PubMedCrossRefGoogle Scholar
  58. 58.
    Ullmann U, Haller J, Decourt JP, et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003 Mar–Apr; 31(2): 88–101PubMedGoogle Scholar
  59. 59.
    Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003 Aug 15; 9(9): 3312–9PubMedGoogle Scholar
  60. 60.
    Pisters KMW, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001; 19: 1830–8PubMedGoogle Scholar
  61. 61.
    Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins (GTCs) in high grade PIN volunteers: a preliminary report from a 1 year proof-of-principle study [abstract presented]. Proceedings of the Annual Meeting of the American Association of Cancer Research; Chicago (IL); 2005Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Nutrition and Department of Cancer Control, H. Lee Moffitt Cancer Center and Research InstituteUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations